Kaplan Matthew L. bought NVCT
June 11, 2026 · Form 4 insider transaction
Kaplan Matthew L. bought 35,000 shares of Nuvectis Pharma, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.
Direction
Acquired (buy-side)
Shares
35,000
Price
$0.00
Total value
N/A
InsiderKaplan Matthew L.
Role—
CompanyNuvectis Pharma, Inc. (NVCT)
SecurityCommon Stock
Transaction codeA: Grant or award
Transaction dateJune 11, 2026
Filing dateJune 12, 2026
Shares owned after159,760
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Kaplan's continued service on the Company's Board of Directors on such dates.; Includes shares of restricted common stock.